News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
715,999 Results
Type
Article (42353)
Company Profile (294)
Press Release (673352)
Section
Business (210385)
Career Advice (2091)
Deals (36626)
Drug Delivery (106)
Drug Development (83022)
Employer Resources (175)
FDA (16553)
Job Trends (15396)
News (355927)
Policy (33885)
Tag
2024 BioCapital Digital (12)
2024 BioForest Digital (4)
2024 BioForest Standard (1)
2024 BioMidwest Digital (9)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (7)
2024 Bio NC Standard (2)
2024 Biotech Bay Standard (18)
2024 Biotech Beach Digital (9)
2024 Biotech Beach Standard (5)
2024 Genetown Digital (8)
2024 Genetown Standard (11)
2024 Lone Star Bio Digital (5)
2024 Pharm Country Digital (6)
2024 Pharm Country Standard (6)
2025 BioForest Digital (3)
2025 Lone Star Bio Digital (6)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Standard (1)
Academia (2590)
Accelerated approval (4)
Adcomms (21)
Allergies (84)
Alliances (51377)
ALS (87)
Alzheimer's disease (1376)
Antibody-drug conjugate (ADC) (117)
Approvals (16554)
Artificial intelligence (249)
Autoimmune disease (18)
Automation (14)
Bankruptcy (371)
Best Places to Work (11770)
BIOSECURE Act (19)
Biosimilars (107)
Biotechnology (188)
Bladder cancer (58)
Brain cancer (27)
Breast cancer (252)
Cancer (2048)
Cardiovascular disease (171)
Career advice (1749)
Career pathing (30)
CAR-T (142)
Cell therapy (404)
Cervical cancer (19)
Clinical research (67281)
Collaboration (789)
Compensation (469)
Complete response letters (25)
COVID-19 (2653)
CRISPR (41)
C-suite (217)
Cystic fibrosis (101)
Data (1989)
Decentralized trials (2)
Denatured (26)
Depression (41)
Diabetes (253)
Diagnostics (6421)
Digital health (17)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (116)
Drug pricing (107)
Drug shortages (28)
Duchenne muscular dystrophy (86)
Earnings (87909)
Editorial (33)
Employer branding (21)
Employer resources (149)
Events (114567)
Executive appointments (663)
FDA (17690)
Featured Employer (50)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (698)
Gene editing (103)
Generative AI (20)
Gene therapy (294)
GLP-1 (724)
Government (4503)
Grass and pollen (4)
Guidances (49)
Healthcare (18992)
Huntington's disease (23)
IgA nephropathy (24)
Immunology and inflammation (113)
Indications (27)
Infectious disease (2786)
Inflammatory bowel disease (136)
Inflation Reduction Act (8)
Influenza (48)
Intellectual property (89)
Interviews (322)
IPO (16762)
IRA (47)
Job creations (4055)
Job search strategy (1492)
Kidney cancer (9)
Labor market (34)
Layoffs (477)
Leadership (16)
Legal (8369)
Liver cancer (71)
Lung cancer (295)
Lymphoma (136)
Machine learning (4)
Management (59)
Manufacturing (281)
MASH (63)
Medical device (13412)
Medtech (13417)
Mergers & acquisitions (20335)
Metabolic disorders (654)
Multiple sclerosis (72)
NASH (17)
Neurodegenerative disease (85)
Neuropsychiatric disorders (26)
Neuroscience (1876)
NextGen: Class of 2025 (6637)
Non-profit (4524)
Northern California (2452)
Now hiring (37)
Obesity (354)
Opinion (226)
Ovarian cancer (73)
Pain (87)
Pancreatic cancer (77)
Parkinson's disease (136)
Partnered (20)
Patents (210)
Patient recruitment (97)
Peanut (49)
People (59076)
Pharmaceutical (91)
Pharmacy benefit managers (19)
Phase I (20864)
Phase II (29601)
Phase III (22193)
Pipeline (1065)
Podcasts (75)
Policy (125)
Postmarket research (2654)
Preclinical (8842)
Press Release (68)
Prostate cancer (95)
Psychedelics (31)
Radiopharmaceuticals (249)
Rare diseases (376)
Real estate (6252)
Recruiting (67)
Regulatory (23009)
Reports (46)
Research institute (2367)
Resumes & cover letters (358)
Rett syndrome (4)
RNA editing (4)
RSV (39)
Schizophrenia (72)
Series A (123)
Series B (79)
Service/supplier (12)
Sickle cell disease (54)
Southern California (2124)
Special edition (15)
Spinal muscular atrophy (150)
Sponsored (29)
Startups (3722)
State (2)
Stomach cancer (14)
Supply chain (61)
Tariffs (13)
The Weekly (47)
United States (21498)
Vaccines (677)
Venture capitalists (37)
Webinars (12)
Weight loss (241)
Women's health (33)
Worklife (15)
Date
Today (92)
Last 7 days (719)
Last 30 days (2759)
Last 365 days (34028)
2025 (8336)
2024 (35770)
2023 (40630)
2022 (51798)
2021 (56329)
2020 (54791)
2019 (47397)
2018 (35770)
2017 (33138)
2016 (32662)
2015 (38616)
2014 (32516)
2013 (27630)
2012 (29729)
2011 (30487)
2010 (28497)
Location
Africa (781)
Alabama (49)
Alaska (7)
Arizona (231)
Arkansas (14)
Asia (40592)
Australia (6502)
California (5592)
Canada (1888)
China (487)
Colorado (250)
Connecticut (257)
Delaware (131)
Europe (86554)
Florida (828)
Georgia (194)
Idaho (57)
Illinois (512)
India (25)
Indiana (300)
Iowa (9)
Japan (146)
Kansas (100)
Kentucky (23)
Louisiana (8)
Maine (61)
Maryland (840)
Massachusetts (4251)
Michigan (211)
Minnesota (372)
Mississippi (2)
Missouri (77)
Montana (27)
Nebraska (25)
Nevada (56)
New Hampshire (62)
New Jersey (1604)
New Mexico (29)
New York (1608)
North Carolina (942)
North Dakota (7)
Northern California (2452)
Ohio (192)
Oklahoma (14)
Oregon (38)
Pennsylvania (1270)
Puerto Rico (9)
Rhode Island (26)
South America (1160)
South Carolina (18)
South Dakota (1)
Southern California (2124)
Tennessee (93)
Texas (840)
Utah (166)
Virginia (138)
Washington D.C. (57)
Washington State (521)
West Virginia (3)
Wisconsin (51)
715,999 Results for "agios pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Agios to Present at Upcoming March 2025 Investor Conferences
March 5, 2025
·
1 min read
Press Releases
Agios to Present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025
February 20, 2025
·
1 min read
Press Releases
Agios Announces Key 2025 Milestones for Innovative Rare Disease Portfolio
January 14, 2025
·
11 min read
Genetown
Agios Pharmaceuticals to Present Clinical and Translational Data in Rare Blood Disorders at European Hematology Association 2024 Hybrid Congress
Agios Pharmaceuticals, Inc., a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, announced that data from its programs will be presented at the European Hematology Association 2024 Hybrid Congress, to be held June 13-16, 2024, in Madrid, Spain.
May 14, 2024
·
8 min read
Genetown
Agios Announces $905 Million Purchase Agreement for Vorasidenib Royalty
Agios Pharmaceuticals, Inc., a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, announced that the company has agreed to sell its rights to its 15% royalty on potential U.S. net sales of Servier’s vorasidenib to Royalty Pharma.
May 28, 2024
·
6 min read
Genetown
Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 14, 2024
Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that the company is scheduled to present at the 2024 RBC Capital Markets Global Healthcare Conference on Tuesday, May 14, 2024, at 8:00 a.m. ET.
May 3, 2024
·
1 min read
Press Releases
Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
February 13, 2025
·
12 min read
Drug Development
Agios Blood Disorder Drug Scores Another Phase III Win
Agios Pharmaceuticals’ Pyrukynd met both the primary and secondary endpoints in patients with transfusion-dependent alpha- or beta-thalassemia.
June 3, 2024
·
2 min read
·
Tyler Patchen
Business
Agios Reports Business Highlights and First Quarter 2024 Financial Results
Agios Pharmaceuticals, Inc., a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, reported business highlights and financial results for the first quarter ended March 31, 2024.
May 2, 2024
·
10 min read
Genetown
Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024
Agios Pharmaceuticals, Inc. today announced that the company is scheduled to present at the Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024, at 1:20 p.m. ET.
May 30, 2024
·
1 min read
1 of 71,600
Next
